CAI
CAI
NASDAQ · Biotechnology

Caris Life Sciences Inc

$24.64
-1.39 (-5.34%)
As of Nov 7, 1:26 AM ET ·
Financial Highlights (FY 2026)
Revenue
1.45B
Net Income
-121,564,288
Gross Margin
66.6%
Profit Margin
-8.4%
Rev Growth
—
D/E Ratio
0.66
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 66.6% 50.6% 50.6% 50.6%
Operating Margin 3.1% 21.1% 22.1% 19.6%
Profit Margin -8.4% 19.3% 20.1% 16.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.45B 1.64B 1.52B 1.76B
Gross Profit 966.03M 830.36M 769.23M 889.64M
Operating Income 45.09M 345.95M 336.69M 344.80M
Net Income -121,564,288 316.28M 306.08M 281.70M
Gross Margin 66.6% 50.6% 50.6% 50.6%
Operating Margin 3.1% 21.1% 22.1% 19.6%
Profit Margin -8.4% 19.3% 20.1% 16.0%
Rev Growth — +14.2% +10.8% -1.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.46B 1.38B 1.27B 1.60B
Total Equity 2.22B 5.23B 4.48B 5.40B
D/E Ratio 0.66 0.26 0.28 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 45.17M 415.16M 429.14M 456.09M
Free Cash Flow — 185.08M 215.40M 287.32M